Previous Article | Next Article ![]()
Journal of Virology, April 2008, p. 3702-3712, Vol. 82, No. 7
0022-538X/08/$08.00+0 doi:10.1128/JVI.01582-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Elizabeth R. Sharp,3
Alison O'Mahony,4
Michael G. Rosenberg,5
Dennis M. Israelski,2,6
Garry P. Nolan,1,
and
Douglas F. Nixon3*,
Baxter Laboratory of Genetic Pharmacology, Department of Microbiology and Immunology,1 Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California 94305,2 Division of Experimental Medicine, UCSF Box 1234, San Francisco, California 94143-1234,3 Gladstone Institute of Virology and Immunology, University of California at San Francisco, 1650 Owens Street, San Francisco, CA 94158-2261,4 Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461,5 San Mateo County San Francisco AIDS Research Center (PARC), San Mateo County General Hospital and Health Department, San Mateo, California 944036
Received 19 July 2007/ Accepted 8 January 2008
Despite extensive evidence of cell signaling alterations induced by human immunodeficiency virus type 1 (HIV-1) in vitro, the relevance of these changes to the clinical and/or immunologic status of HIV-1-infected individuals is often unclear. As such, mapping the details of cell type-specific degradation of immune function as a consequence of changes to signaling network responses has not been readily accessible. We used a flow cytometric-based assay of signaling to determine Janus kinase/signal transducers and activators of transcription (Jak/STAT) signaling changes at the single-cell level within distinct cell subsets from the primary immune cells of HIV-1-infected donors. We identified a specific defect in granulocyte-macrophage colony-stimulating factor (GM-CSF)-driven Stat5 phosphorylation in the monocytes of HIV-1+ donors. This inhibition was statistically significant in a cohort of treated and untreated individuals. Ex vivo Stat5 phosphorylation levels varied among HIV-1+ donors but did not correlate with CD4+ T-cell counts or HIV-1 plasma viral load. Low Stat5 activation occurred in HIV-1-infected donors despite normal GM-CSF receptor levels. Investigation of mitogen-activated protein kinase (MAPK) pathways, also stimulated by GM-CSF, led to the observation that lipopolysaccharide-stimulated extracellular signal-regulated kinase phosphorylation is enhanced in monocytes. Thus, we have identified a specific, imbalanced monocyte signaling profile, with inhibition of STAT and enhancement of MAPK signaling, associated with HIV-1 infection. This understanding of altered monocyte signaling responses that contribute to defective antigen presentation during HIV-1 infection could lead to immunotherapeutic approaches that compensate for the deficiency.
Published ahead of print on 23 January 2008.
Present address: Merck Research Laboratories, Infectious Diseases/Vaccines Clinical Research, 351 Sumneytown Pike, North Wales, PA 19454.
G.P.N. and D.F.N. contributed equally to this study.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»